NDLI: Drug discovery and development for neglected diseases: the DNDi model

Content Provider	PubMed Central
Author	Chatelain, Eric Ioset, Jean-robert
Copyright Year	2011
Abstract	New models of drug discovery have been developed to overcome the lack of modern and effective drugs for neglected diseases such as human African trypanosomiasis (HAT; sleeping sickness), leishmaniasis, and Chagas disease, which have no financial viability for the pharmaceutical industry. With the purpose of combining the skills and research capacity in academia, pharmaceutical industry, and contract researchers, public–private partnerships or product development partnerships aim to create focused research consortia that address all aspects of drug discovery and development. These consortia not only emulate the projects within pharmaceutical and biotechnology industries, eg, identification and screening of libraries, medicinal chemistry, pharmacology and pharmacodynamics, formulation development, and manufacturing, but also use and strengthen existing capacity in disease-endemic countries, particularly for the conduct of clinical trials. The Drugs for Neglected Diseases initiative (DNDi) has adopted a model closely related to that of a virtual biotechnology company for the identification and optimization of drug leads. The application of this model to the development of drug candidates for the kinetoplastid infections of HAT, Chagas disease, and leishmaniasis has already led to the identification of new candidates issued from DNDi’s own discovery pipeline. This demonstrates that the model DNDi has been implementing is working but its DNDi, neglected diseases sustainability remains to be proven.
Related Links	http://dx.doi.org/10.2147/dddt.s16381
Ending Page	181
Starting Page	175
File Format	PDF
ISSN	11778881
e-ISSN	11778881
Journal	Drug Design, Development and Therapy
Volume Number	5
Language	English
Publisher	Dove Medical Press
Publisher Date	2011-03-01
Access Restriction	Open
Rights Holder	Dove Medical Press
Subject Keyword	Pharmacology Drug Discovery Pharmaceutical Science Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Drug Discovery Pharmacology Pharmaceutical Science

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Drug discovery and development for neglected diseases: the DNDi model

Drug discovery and development for neglected diseases: the DNDi model.

Drug discovery and development for neglected diseases: the DNDi model

Development and use of sulodexide in vascular diseases: implications for treatment

Drug Development to Protozoan Diseases

Exposure–response model for sibutramine and placebo: suggestion for application to long-term weight-control drug development

International Partnership for Therapeutic Drug Development of NTDs by DNDi

Drug discovery for neglected tropical diseases at the Sandler Center

Target repurposing for neglected diseases

Drug discovery and development for neglected diseases: the DNDi model

Similar Documents

Drug discovery and development for neglected diseases: the DNDi model

Drug discovery and development for neglected diseases: the DNDi model.

Drug discovery and development for neglected diseases: the DNDi model

Development and use of sulodexide in vascular diseases: implications for treatment

Drug Development to Protozoan Diseases

Exposure–response model for sibutramine and placebo: suggestion for application to long-term weight-control drug development

International Partnership for Therapeutic Drug Development of NTDs by DNDi

Drug discovery for neglected tropical diseases at the Sandler Center

Target repurposing for neglected diseases

Drug discovery and development for neglected diseases: the DNDi model